Paul Edward Walker has bought stock on 12 days since May 2019
10% owner at Korro Bio, Inc., and 10 other companies
SEC CIK 0001553150 · Filings on SEC.gov ↗
Paul Edward Walker's record
3 months after each buy, from the first price a copier could get.
6 buys since 2019 with 3 months of prices.
Companies
- KRRO Korro Bio, Inc.10% owner
- SGP SpyGlass Pharma, Inc.10% owner
- MBX MBX Biosciences, Inc.10% owner
- SVRA Savara Inc.10% owner
- ALLK Allakos Inc.Director
- GNCA Genocea Biosciences, Inc.10% owner
- TRVI Trevi Therapeutics, Inc.10% owner
- MTCR Metacrine, Inc.10% owner
- MRKR Marker Therapeutics, Inc.10% owner
- RGLS Regulus Therapeutics Inc.10% owner
- AKUS Akouos, Inc.10% owner
Every filing
15 filings since May 2019, newest first
Korro Bio, Inc.
10% owner
Spyglass Pharma, Inc.
10% owner
Mbx Biosciences, Inc.
10% owner
Korro Bio, Inc.
10% owner
Savara Inc
10% owner
Allakos Inc.
Director
Genocea Biosciences, Inc.
10% owner
Trevi Therapeutics, Inc.
10% owner
Metacrine, Inc.
10% owner
Marker Therapeutics, Inc.
10% owner
Allakos Inc.
Director
Regulus Therapeutics Inc.
10% owner
Akouos, Inc.
10% owner
Trevi Therapeutics, Inc.
10% owner
Regulus Therapeutics Inc.
10% owner
About Paul Edward Walker
Paul Edward Walker is a prominent venture capitalist and 10% owner of SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company focused on treatments for chronic eye conditions.( He filed an initial Form 3 on February 5, 2026, disclosing indirect holdings of multiple series of preferred stock in SGP, which converted to common stock ahead of the company's IPO.(
On February 9, 2026, entities linked to Walker indirectly purchased 937,500 shares of SGP common stock at $16 per share, increasing those holdings to approximately 6 million shares and solidifying his significant stake, reported as both director and beneficial owner (BO).( Walker is associated with New Enterprise Associates (NEA) funds, granting him substantial influence through indirect ownership, and has been highlighted alongside other major investors in recent SGP insider activities.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.